Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-cash Items (2016 - 2025)

Viking Therapeutics' Non-cash Items history spans 11 years, with the latest figure at $114.0 million for Q4 2025.

  • For Q4 2025, Non-cash Items fell 19.32% year-over-year to $114.0 million; the TTM value through Dec 2025 reached $114.0 million, down 19.32%, while the annual FY2025 figure was $114.0 million, 6010.36% up from the prior year.
  • Non-cash Items for Q4 2025 was $114.0 million at Viking Therapeutics, up from $75.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $60.3 billion in Q1 2023 and bottomed at $1.1 million in Q3 2022.
  • The 5-year median for Non-cash Items is $3.9 million (2021), against an average of $4.2 billion.
  • The largest annual shift saw Non-cash Items surged 2099555.96% in 2023 before it plummeted 99.99% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $2.9 million in 2021, then surged by 611.09% to $20.5 million in 2022, then soared by 203.24% to $62.2 million in 2023, then surged by 127.13% to $141.3 million in 2024, then dropped by 19.32% to $114.0 million in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Non-cash Items are $114.0 million (Q4 2025), $75.0 million (Q3 2025), and $2.9 million (Q2 2025).